Trial · NCT06963502
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
NCT06963502, Phase 1, Not yet recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors. Trials, record NCT06963502. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06963502
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors
- NCT number
- NCT06963502
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 762 participants, estimated
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
- Interventions
- HS-10370, HS-20117, Adebrelimab, Capecitabine, Oxaliplatin, Folinic Acid, Fluorouracil and Oxaliplatin/Irinotecan, HS-20093, platinum (cisplatin or carboplatin)
- First posted
- 2025-05-09
- Last updated
- 2025-05-09
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants with Adverse Event(s) (AEs) | From Cycle 1 Day 1 (C1D1) to disease progression or death, up to 2 years (each cycle is 14 days). | An adverse event (AE) is defined as any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) |
| Secondary | Overall Response Rate (ORR) | From Cycle 1 Day 1 (C1D1) to disease progression or death, up to 2 years (each cycle is 14 days). | Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR).ORR by the Investigator According to RECIST v1.1 |
| Secondary | Disease Control Rate (DCR) | From Cycle 1 Day 1 (C1D1) to disease progression or death, up to 2 years (each cycle is 14 days). | Percentage of Participants who Achieve a BOR of CR, PR, or Stable Disease (SD).DCR by the Investigator According to RECIST v1.1 |
| Secondary | Time to Response (TTR) | Time from Cycle 1 Day 1 until the date that measurement criteria for CR or PR (whichever is first recorded) are first met, up to 2 years (each cycle is 14 days). | TTR by the Investigator According to RECIST v1.1 |
| Secondary | Duration of Response (DOR) | Date of first evidence of CR or PR to date of disease progression or death from any cause, approximately 2 years | DOR by the Investigator According to RECIST v1.1 |
| Secondary | Progression-Free Survival (PFS) | Date of first evidence of CR or PR to date of disease progression or death from any cause, approximately 2 years | PFS by the Investigator According to RECIST v1.1 |
| Secondary | Overall survival (OS) | Cycle 1 Day 1 to date of death from any cause, up to 5 years (each cycle is 14 days) | Defined as the time from C1D1 to death from any cause by the Investigator According to RECIST v1.1 |
| Secondary | Plasma Concentrations of HS-10370 | Cycle 1 Day 1 to date of death from any cause. Various timepoints from Cycle 1 Day 1 through study treatment discontinuation, up to 2 years. (each cycle is 14 days) | Defined as the time from C1D1 to death from any cause |
| Secondary | Maximum plasma concentration (Cmax) | Cycle 1 Day 1 to date of death from any cause, up to 2 years. Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (each cycle is 14 days) | Cmax is defined as maximum observed serum concentration obtained directly from the observed concentration-time data. |
| Secondary | Time of maximum concentration (Tmax) | Cycle 1 Day 1 to date of death from any cause, up to 2 years. Various timepoints from Cycle 1 Day 1 through study treatment discontinuation (each cycle is 14 days) | Tmax is defined as the time required for a drug to reach peak concentration in plasma. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06963502
GET https://conductscience.org/api/trials/v1/NCT06963502/registered